Clinical pharmacokinetics of therapeutic monoclonal antibodies RJ Keizer, ADR Huitema, JHM Schellens, JH Beijnen Clinical pharmacokinetics 49, 493-507, 2010 | 764 | 2010 |
Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose RJ Keizer, MO Karlsson, A Hooker CPT: pharmacometrics & systems pharmacology 2 (6), 1-9, 2013 | 673 | 2013 |
Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM RJ Keizer, M Van Benten, JH Beijnen, JHM Schellens, ADR Huitema Computer methods and programs in biomedicine 101 (1), 72-79, 2011 | 360 | 2011 |
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis IH Bartelink, A Lalmohamed, EML van Reij, CC Dvorak, RM Savic, ... The Lancet Haematology 3 (11), e526-e536, 2016 | 242 | 2016 |
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients TPC Dorlo, PPAM van Thiel, ADR Huitema, RJ Keizer, HJC de Vries, ... Antimicrobial agents and chemotherapy 52 (8), 2855-2860, 2008 | 199 | 2008 |
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses RJ Keizer, RS Jansen, H Rosing, B Thijssen, JH Beijnen, JHM Schellens, ... Pharmacology research & perspectives 3 (2), e00131, 2015 | 169 | 2015 |
Model‐informed precision dosing at the bedside: scientific challenges and opportunities RJ Keizer, R Ter Heine, A Frymoyer, LJ Lesko, R Mangat, S Goswami CPT: pharmacometrics & systems pharmacology 7 (12), 785-787, 2018 | 112 | 2018 |
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice DJ Buurman, JM Maurer, RJ Keizer, JGW Kosterink, G Dijkstra Alimentary pharmacology & therapeutics 42 (5), 529-539, 2015 | 79 | 2015 |
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 RJ Keizer, A Gupta, MR Mac Gillavry, M Jansen, J Wanders, JH Beijnen, ... Journal of pharmacokinetics and pharmacodynamics 37, 347-363, 2010 | 65 | 2010 |
The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin JE Hibma, AA Zur, RA Castro, MB Wittwer, RJ Keizer, SW Yee, ... Clinical pharmacokinetics 55, 711-721, 2016 | 60 | 2016 |
Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children’s hospital A Frymoyer, HT Schwenk, Y Zorn, L Bio, JD Moss, B Chasmawala, ... Frontiers in Pharmacology 11, 551, 2020 | 47 | 2020 |
Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses RJ Keizer, AS Zandvliet, JH Beijnen, JHM Schellens, ADR Huitema The AAPS journal 14, 601-611, 2012 | 46 | 2012 |
Individualized empiric vancomycin dosing in neonates using a model-based approach A Frymoyer, C Stockmann, AL Hersh, S Goswami, RJ Keizer Journal of the Pediatric Infectious Diseases Society 8 (2), 97-104, 2019 | 45 | 2019 |
Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 43 | 2015 |
New paradigm for translational modeling to predict long‐term tuberculosis treatment response IH Bartelink, N Zhang, RJ Keizer, N Strydom, PJ Converse, KE Dooley, ... Clinical and translational science 10 (5), 366-379, 2017 | 40 | 2017 |
Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients R Ter Heine, RJ Keizer, K van Steeg, EJ Smolders, M van Luin, HJ Derijks, ... British journal of clinical pharmacology 86 (12), 2497-2506, 2020 | 39 | 2020 |
A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors JH Hughes, RJ Keizer CPT: pharmacometrics & systems pharmacology 10 (10), 1150-1160, 2021 | 38 | 2021 |
Continuous learning in model‐informed precision dosing: a case study in pediatric dosing of vancomycin JH Hughes, DMH Tong, SS Lucas, JD Faldasz, S Goswami, RJ Keizer Clinical Pharmacology & Therapeutics 109 (1), 233-242, 2021 | 37 | 2021 |
Oxymorphone active uptake at the blood–brain barrier and population modeling of its pharmacokinetic–pharmacodynamic relationship MW Sadiq, E Boström, R Keizer, S Bjorkman, M Hammarlund-Udenaes Journal of pharmaceutical sciences 102 (9), 3320-3331, 2013 | 37 | 2013 |
Personalized tuberculosis treatment through model-informed dosing of rifampicin SW van Beek, R Ter Heine, RJ Keizer, C Magis-Escurra, RE Aarnoutse, ... Clinical pharmacokinetics 58, 815-826, 2019 | 33 | 2019 |